Sara Carolina Henriques

Dr. Sara Carolina Henriques

Faculty of Pharmacy, University of Lisbon, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
FPFilipe Palavra
Filipe Palavra
SVSofia D. Viana
Sofia D. Viana
Sara Carolina HenriquesSara Carolina Henriques
Sara Carolina Henriques
JDJoão Dinis
João Dinis
JMJoão Martins
João Martins
Flávio ReisFlávio Reis
Flávio Reis
Cuprizone (CPZ) is a copper chelator used to produce a reversible oligodendrocytopathy in animals, which has some similarities to the pathology found in human multiple sclerosis (MS). This model is attractive to study remyelination. To demonstrate that a two-week period after cessation of CPZ exposure is sufficient to establish changes compatible with remyelination, without accompanying behavior or brain magnetic resonance imaging (MRI) disturbances. Two groups of male C57BL/6 mice were fed an oral solution of CPZ (0.2%) for 5 weeks (W5); half of the animals were kept under the vehicle for another 2 weeks (W7). After 5 and 7 weeks, animals were subjected to a battery of behavioural tests and 18 animals to brain MRI. Animals' cerebellar samples were studied for gene expression and/or protein levels of GFAP, myelin proteolipid protein (PLP), TNF-α and IL-1β. No differences were observed between CPZ-exposed and control animals, regarding behavior and MRI, both at W5 and W7. However, myelin PLP levels decreased in CPZ (W5) treated animals, and these changes reverted at W7. GFAP levels varied in the opposite direction. Observed changes validate the use of W5 and W7 temporal moments for the study of demyelination and early remyelination in this model.

13 June 2020 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
CMCristina De Mello-Sampayo
Cristina De Mello-Sampayo
AVAna Rita Vaz
Ana Rita Vaz
Sara Carolina HenriquesSara Carolina Henriques
Sara Carolina Henriques
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
FPFabiana Paradinha
Fabiana Paradinha
ALAlvaro Lopes
Alvaro Lopes

1 November 2020 in Journal of Chromatography B
Verified
Journal Article
Closed access
JCJoana Carrola
Joana Carrola
Noelia DuarteNoelia Duarte
Noelia Duarte
PFPedro R. Florindo
Pedro R. Florindo
Sara Carolina HenriquesSara Carolina Henriques
Sara Carolina Henriques
GSGustavo da Silva
Gustavo da Silva
MBMaria Do Rosário Bronze
Maria Do Rosário Bronze

14 June 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
OCOlga Cardoso
Olga Cardoso
MDMaria Manuel Donato
Maria Manuel Donato
Sara Carolina HenriquesSara Carolina Henriques
Sara Carolina Henriques
Fernando RamosFernando Ramos
Fernando Ramos
The presence of fluoroquinolone (FQ) residues in food-producing animals has raised concerns regarding antimicrobial resistance. This study evaluated the occurrence of FQ residues in the liver and kidneys of piglets and their association with resistance patterns in Escherichia coli and Enterococcus species from piglets’ intestinal microbiota. FQ residues were found in 44% of livers and 23% of kidneys. Among 340 E. coli isolates from feces, resistance to ciprofloxacin (CIP) (43.2%) and multidrug resistance (MDR) (82.7%) were prominent. The presence of FQ in kidneys significantly increased the odds of CIP-resistant E. coli (OR = 2.94, p = 0.0013) and MDR (OR = 2.70, p = 0.0047). Enterococci (n = 130) were evenly distributed among the species E. faecalis, E. faecium, and Enterococcus spp. and presented resistance to CIP (34.6%). FQ in kidneys were associated with higher odds of CIP-resistant enterococci (OR = 3.78, p = 0.015). Interaction models revealed species-dependent responses, with Enterococcus spp. showing high resistance in the presence of FQ in kidneys (OR = 18, p = 0.006), while E. faecium exhibited lower resistance compared to E. faecalis. These findings emphasize the role of FQ residues in promoting bacterial resistance and underscore the need for the stricter regulation and routine surveillance of antimicrobial use in livestock to curb the spread of bacterial resistance to clinical drugs, and mitigate public health risks—One Health.

7 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Sara Carolina HenriquesSara Carolina Henriques
Sara Carolina Henriques
JAJoão Albuquerque
João Albuquerque
PPPaulo Paixão
Paulo Paixão
LALuís Almeida
Luís Almeida
NSNuno Miguel Elvas Neves Silva
Nuno Miguel Elvas Neves Silva
Pilot bioavailability/bioequivalence (BA/BE) studies are usually conducted and analysed similarly to pivotal studies. Their analysis and interpretation of results usually rely on the application of the average bioequivalence approach. However, due to the small study size, pilot studies are inarguably more sensitive to variability. The aim of this work is to propose alternative approaches to the average bioequivalence methodology, in a way to overcome and reduce the uncertainty on the conclusions of these studies and on the potential of test formulations. Several scenarios of pilot BA/BE crossover studies were simulated through population pharmacokinetic modelling. Each simulated BA/BE trial was analysed using the average bioequivalence approach. As alternative analyses, the centrality of the test-to-reference geometric least square means ratio (GMR), bootstrap bioequivalence analysis, and arithmetic (Amean) and geometric (Gmean) mean ƒ2 factor approaches were investigated. Methods performance was measured with a confusion matrix. The Gmean ƒ2 factor using a cut-off of 35 was the most appropriate method in the simulation conditions frame, enabling to more accurately conclude the potential of test formulations, with a reduced sample size. For simplification, a decision tree is also proposed for appropriate planning of the sample size and subsequent analysis approach to be followed in pilot BA/BE trials.

6 July 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
MFMarlene Fonseca
Marlene Fonseca
CRCheila Ribeiro
Cheila Ribeiro
GCGuillermo Castilla‐Fernández
Guillermo Castilla‐Fernández
HGHelena Gama
Helena Gama
LMLuís Magalhães
Luís Magalhães
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva